Up-regulation of activating and inhibitory NKG2 receptors in allogeneic and autologous hematopoietic stem cell grafts

Table 2 Autotransplanted patients

Patient	Age	Diagnosis^a	Status at transplant^b	Source of graft^c	Conditioning regimen^d	Relapse (days)	Last follow up (days)	Status at last follow up	Cause of death
187	60	AML	1st CR	PB	IBU	305	426	Dead	Relapse/Progression
188	19	DLBCL	1st PR	PB	BEAM	no	1159	Alive
189	25	NHL	1st CR	PB	BEAM	no	1152	Alive
190	50	HL	2nd CR	PB	BEAM	no	1149	Alive
191	51	MM	1st PR	PB	MEL200	861	1239	Dead	Relapse/Progression

^aAML, Acute Myeloid Leukemia; DLBCL, Diffuse Large B Cell Lymphoma; NHL, Non-Hodgkin’s Lymphoma; HL, Hodgkin’s Lymphoma; MM, multiple myeloma
^bCR, complete remission; PR, partial remission
^cPB: CD34⁻ peripheral blood autologous stem cells
^dBEAM: Carmustine, Etoposide, Cytarabine, Melphalan; IBU: Idarubicine, Busulphan; MEL200: Melphalan

ISSN: 1756-9966